Page last updated: 2024-11-13
unc 0321
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
7-(2-(2-(dimethylamino)ethoxy)ethoxy)-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine: a G9a antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 46901937 |
| CHEMBL ID | 1214066 |
| CHEBI ID | 94307 |
| SCHEMBL ID | 16512777 |
| MeSH ID | M0549681 |
Synonyms (28)
| Synonym |
|---|
| CHEMBL1214066 , |
| NCGC00187789-01 |
| bdbm50323813 |
| 7-(2-(2-(dimethylamino)ethoxy)ethoxy)-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-n-(1-methylpiperidin-4-yl)quinazolin-4-amine |
| BRD-K74236984-001-01-4 |
| HY-10930 |
| unc 0321 |
| unc-0321 |
| unc0321 |
| SCHEMBL16512777 |
| 7-[2-[2-(dimethylamino)ethoxy]ethoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-n-(1-methylpiperidin-4-yl)quinazolin-4-amine |
| gtpl8389 |
| 1238673-32-9 |
| AKOS030526346 |
| 7-{2-[2-(dimethylamino)ethoxy]ethoxy}-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-n-(1-methylpiperidin-4-yl)quinazolin-4-amine |
| CHEBI:94307 |
| unc0321(tfa salt) |
| BCP24241 |
| EX-A7316 |
| Q27089085 |
| BCP12391 |
| SB19348 |
| F85003 |
| MS-29574 |
| YSZC347 |
| A927576 |
| DTXSID201025974 |
| AC-35493 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (10)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 36.2529 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
| TDP1 protein | Homo sapiens (human) | Potency | 35.4813 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 28.1838 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 50.1187 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0150 | 0.0004 | 0.2147 | 4.0000 | AID497477 |
| Protein arginine N-methyltransferase 3 | Homo sapiens (human) | IC50 (µMol) | 40.0000 | 0.0190 | 1.2995 | 7.1000 | AID497482 |
| Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | IC50 (µMol) | 40.0000 | 0.0020 | 2.5266 | 6.0800 | AID497480 |
| Histone-lysine N-methyltransferase EHMT2 | Homo sapiens (human) | IC50 (µMol) | 6.5022 | 0.0025 | 1.1480 | 9.2000 | AID497473; AID497475; AID618483; AID618490 |
| Histone-lysine N-methyltransferase EHMT1 | Homo sapiens (human) | IC50 (µMol) | 0.0190 | 0.0130 | 0.7995 | 4.9000 | AID497474; AID497477 |
| N-lysine methyltransferase KMT5A | Homo sapiens (human) | IC50 (µMol) | 40.0000 | 0.2100 | 2.3738 | 9.0000 | AID497481 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (41)
Molecular Functions (29)
Ceullar Components (10)
Bioassays (12)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID497473 | Inhibition of methyl transferase activity of G9a assessed as inhibition of H3K9 methylation by chemiluminescence based oxygen tunneling assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| AID497475 | Activity at methyl transferase activity G9a by enzyme coupled S-adenocylehomocystein detection assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| AID497477 | Activity at methyl transferase activity GLP by enzyme coupled S-adenocylehomocystein detection assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| AID497481 | Activity at methyl transferase activity SET8/preSet7 by enzyme coupled S-adenocylehomocystein detection assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| AID497474 | Activity at methyl transferase activity GLP by chemiluminescence based oxygen tunneling assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| AID497480 | Activity at methyl transferase activity SET7/9 by enzyme coupled S-adenocylehomocystein detection assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| AID497482 | Activity at methyl transferase activity PRMT3 by enzyme coupled S-adenocylehomocystein detection assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| AID497483 | Activity at methyl transferase activity JMJD2E by enzyme coupled S-adenocylehomocystein detection assay | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| AID618483 | Inhibition of G9a assessed as hydrolysis of S-adenosyl-L-homocysteine after 2 mins by SAHH-coupled fluorescence assay | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. |
| AID618490 | Inhibition of G9a in human MDA-MB-231 cells assessed as reduction of H3K9me2 after 48 hrs by In-Cell Western assay | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. |
| AID618491 | Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by MTT assay | 2011 | Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17 | Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. |
| AID1346126 | Human euchromatic histone lysine methyltransferase 2 (2.1.1.43 Histone methyltransferases (HMTs)) | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.28) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||